Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction.

"Disclosures Dr Lerman serves as a consultant to Phillps/Volcano and Itamar Medical. Dr Bairey Merz reports consulting for Abbott, Sanofi and serves on the board of iRhthym. Dr Henry serves as a consultant to Caladrius Biosciences, Inc. Dr Sietsema, Dr Wang, Dr Takagi, Dr Lee, Dr Losordo, Ms. Kotynski, Ms. Lewis, Ms. Schumacher, Ms. Bartel, and Mr Shah all reports grants from NIH- National Heart, Lung, and Blood institute during the conduct of the study; other from Caladrius Biosciences, Inc., outside the submitted work. Dr Corban, Dr Quesada, Dr Lerman, Dr Wei and Ms. Juong have nothing to disclose."

"Sources of Funding This work was supported by Caladrius Biosciences, Inc. and by the National Heart, Lung, and Blood Institute at the NIH under award numbers R44HL135889 and K23HL151867 (OQ). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH."

"Registration:: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03508609."